We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




New Blood Test Promises Biopsy-Free Colon Cancer Diagnosis

By LabMedica International staff writers
Posted on 11 May 2021
A newly developed liquid biopsy test detects persistent circulating tumor DNA (ctDNA) after curative surgery and can identify patients with minimal residual disease (MRD) who will ultimately relapse.

Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations and to facilitate ctDNA detection. More...
This approach requires both a biopsy sample from the tumor and blood. To eliminate the need for a sample of the tumor, investigators at Massachusetts General Hospital (Boston, USA) evaluated a plasma-only ctDNA assay, which combined genomic and epigenomic cancer signatures to enable "tumor-uninformed" MRD detection.

For this study, the investigators analyzed 252 prospective serial plasma specimens from 103 colorectal cancer (CRC) patients undergoing curative surgery, and the results were correlated with tumor recurrence. From the original group of 103 patients, 84 patients with cancers of various stages had plasma drawn post-completion of definitive therapy, defined as surgery only or completion of adjuvant therapy.

Results revealed that in "landmark" plasma drawn approximately one-month post-definitive therapy and followed up a year later, 15 patients had detectable ctDNA, and all 15 recurred. Of 49 patients without detectable ctDNA at the landmark timepoint, 12 recurred. Landmark recurrence sensitivity and specificity were 55.6% and 100%. Integrating epigenomic signatures increased sensitivity by 25-36% versus genomic alterations alone. Notably, the standard measurement of serum carcinoembryonic antigen (CEA) levels did not predict cancer recurrence.

For this study, the investigators used the Guardant Health (Redwood City, CA, USA) Reveal assay. This test has reportedly achieved industry-leading sensitivity (91%) for detecting ctDNA by simultaneously interrogating both genomic alterations and methylation. Results were obtained from a simple blood draw and returned in as little as seven days without the need for a tissue biopsy. Thus, the test improved the management of early-stage CRC patients by detecting circulating tumor DNA in blood after surgery to identify patients with residual disease who may benefit most from adjuvant therapy, and by detecting recurrence months earlier than current standard-of-care methods like CEA tests or imaging.

"The use of ctDNA, which is a type of "liquid biopsy", is a powerful prognostic tool to detect residual disease, and many prospective trials are under way in the United States, Europe, Asia, and Australia to use ctDNA to guide treatment decision-making," said first author Dr, Aparna R. Parikh, an oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School. "Most studies have used a tumor-informed ctDNA approach that requires testing of the tumor and knowledge of tumor-specific alterations, which cannot be used when a patient has insufficient tumor tissue for analysis. This is one of the first studies to report on a plasma-only approach. There are advantages and disadvantages to each of the approaches."

The tumor-uninformed liquid biopsy was described in the April 29, 2021, online edition of the journal Clinical Cancer Research

Related Links:
Massachusetts General Hospital
Guardant Health



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.